Impress delivered a strong start to 2026, reporting a solid first quarter alongside the opening of a new office designed to support high‑pace, in‑person collaboration. The healthtech and orthodontics company emphasized rapid execution and product development as it scales its AI‑enabled clear aligner platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The firm reiterated its position as Europe’s largest invisible orthodontics brand, serving more than 250,000 patients annually across 10 countries. Management outlined plans to open 20 new clinics across Europe and to enter the U.S. market this year, a move that could expand revenue and brand visibility while increasing near‑term fixed costs.
Impress continued to invest in its operating platform, with the new office framed as a hub for creativity, teamwork, and future hiring to support growth. Its AI system, trained on hundreds of thousands of patient cases, is intended to enhance clinical decision‑making, improve treatment quality, and reduce costs across its network.
The company also gained external recognition by being named to Endeavor’s 2026 Outliers list of “Spanish champions,” placing it among the top 10% of entrepreneurs in Endeavor’s global network. This endorsement supports its positioning as a revenue‑driven growth business within Spain’s high‑impact ecosystem rather than one focused solely on valuation.
On the talent front, Impress showcased its model and career paths to more than 85 dental students and future orthodontists at Karolinska Institutet in Sweden. The outreach underscored digital innovation, clinical excellence, and patient‑centric care, strengthening its appeal as an employer and supporting long‑term pipeline needs as it expands.
Overall, the week’s developments point to a company doubling down on geographic expansion, AI‑driven clinical capabilities, and organizational capacity. While detailed financial metrics remain limited, Impress’s strategy appears centered on scaling its clinic network and technology while maintaining operational efficiency and clinical quality, marking a notably constructive week for its growth trajectory.

